A Phase I Study of SPGL008 in Subjects With Advanced Malignant Tumors

Recruiting now · Phase 1

Conditions studied: Advanced Malignant Tumors

In brief

This study includes two cohorts, respectively evaluating safety, tolerability and preliminary efficacy of intravenous and subcutaneous administration of SPGL008.

Key facts

Study ID

NCT07038005

Run by

Shenyang Sunshine Pharmaceutical Co., LTD.

People needed

96

Starts

2025-07-30

Expected to finish

2027-06-08

Last updated by the study team

2026-02-09

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Males and/or females, 18-75 years old;
• Histologically and/or cytologically documented advanced or metastatic malignant Tumors;
• Eastern Cooperative Oncology Group (ECOG) performance status of 0-1;
• Expected survival >=3 months;
• Signed informed consent form.

You may not qualify if…

• Known uncontrolled or symptomatic central nervous system metastatic disease;
• Adverse events (with exception of alopecia and fatigue) from any prior anticancer therapy of grade >1 (National Cancer Institute Common terminology Criteria [NCI-CTCAE] v.5.0);
• Inadequate organ or bone marrow function;
• Pregnant or breast-feeding woman;
• Known allergies, hypersensitivity, or intolerance to SPGL008.

Where it is running

• Chongqing University Cancer Hospital — Chongqing, Chongqing Municipality, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.